Synthesis of Lenacapavir Sodium: Active Pharmaceutical Ingredient Process Development and Scale-up
Lenacapavir sodium (GS-6207-02) is a first-in-class HIV capsid inhibitor. Process development of the four-step final assembly of lenacapavir sodium from four synthetic intermediates is described here. A bis-bromopyridine core is sequentially subjected to an alkynylation, an amide coupling with a chi...
Gespeichert in:
| Veröffentlicht in: | Organic process research & development 2024-08, Vol.28 (8), p.3382-3395 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 3395 |
|---|---|
| container_issue | 8 |
| container_start_page | 3382 |
| container_title | Organic process research & development |
| container_volume | 28 |
| creator | Wagner, Anna M. Bonderoff, Sara A. Chang, Stanley Deignan, Jeffrey Esanu, Michelle M. Van Huynh, Huy Niu, Tianmin Ngo, Vinh O’Keefe, B. Michael Phoenix, Jenny Rainey, Trevor J. Roberts, Benjamin J. Shen, Jinyu Stewart, Craig Vandehey, Amanda L. Wolckenhauer, Scott A. Wong, Chloe Y. Yarmuch, Brian H. |
| description | Lenacapavir sodium (GS-6207-02) is a first-in-class HIV capsid inhibitor. Process development of the four-step final assembly of lenacapavir sodium from four synthetic intermediates is described here. A bis-bromopyridine core is sequentially subjected to an alkynylation, an amide coupling with a chiral pyrazole carboxylic acid, and a Suzuki cross-coupling with an indazole boronic ester. The final step is a telescoped bis-methanesulfonylation and hydrolysis to yield the API. This report highlights experimental work on the final assembly sequence to establish robust processing conditions, minimize process mass intensity, control impurity formation, understand impurity purge, and enable large-scale manufacturing of lenacapavir sodium. |
| doi_str_mv | 10.1021/acs.oprd.4c00242 |
| format | Article |
| fullrecord | <record><control><sourceid>acs_cross</sourceid><recordid>TN_cdi_crossref_primary_10_1021_acs_oprd_4c00242</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>d184984191</sourcerecordid><originalsourceid>FETCH-LOGICAL-a163t-a89951d9d01be0c0a38f82ed0928686671770b4668812cef15e36bdcd720d5be3</originalsourceid><addsrcrecordid>eNp1kFFLwzAUhYMoOKfvPuYH2HmTrmnq25hOBwUHU_CtpMmty1ibkrSD_Xtbtlef7uXecw6Hj5BHBjMGnD0rHWau9WY21wB8zq_IhCUcokSKn-thBxlHggm4JXch7AEgEYxPSLk9Nd0Ogw3UVTTHRmnVqqP1dOuM7esXutCdPSLd7JSvlca-s1od6Lr59WgsNh3deKcxBPqKRzy4th5vqjF0O-gw6tt7clOpQ8CHy5yS79Xb1_Ijyj_f18tFHikm4i5SMssSZjIDrETQoGJZSY4GMi6FFCJlaQrlXAgpGddYsQRjURptUg4mKTGeEjjnau9C8FgVrbe18qeCQTEyKgZGxciouDAaLE9ny_jZu943Q8H_5X9sCGwV</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Synthesis of Lenacapavir Sodium: Active Pharmaceutical Ingredient Process Development and Scale-up</title><source>ACS Publications</source><creator>Wagner, Anna M. ; Bonderoff, Sara A. ; Chang, Stanley ; Deignan, Jeffrey ; Esanu, Michelle M. ; Van Huynh, Huy ; Niu, Tianmin ; Ngo, Vinh ; O’Keefe, B. Michael ; Phoenix, Jenny ; Rainey, Trevor J. ; Roberts, Benjamin J. ; Shen, Jinyu ; Stewart, Craig ; Vandehey, Amanda L. ; Wolckenhauer, Scott A. ; Wong, Chloe Y. ; Yarmuch, Brian H.</creator><creatorcontrib>Wagner, Anna M. ; Bonderoff, Sara A. ; Chang, Stanley ; Deignan, Jeffrey ; Esanu, Michelle M. ; Van Huynh, Huy ; Niu, Tianmin ; Ngo, Vinh ; O’Keefe, B. Michael ; Phoenix, Jenny ; Rainey, Trevor J. ; Roberts, Benjamin J. ; Shen, Jinyu ; Stewart, Craig ; Vandehey, Amanda L. ; Wolckenhauer, Scott A. ; Wong, Chloe Y. ; Yarmuch, Brian H.</creatorcontrib><description>Lenacapavir sodium (GS-6207-02) is a first-in-class HIV capsid inhibitor. Process development of the four-step final assembly of lenacapavir sodium from four synthetic intermediates is described here. A bis-bromopyridine core is sequentially subjected to an alkynylation, an amide coupling with a chiral pyrazole carboxylic acid, and a Suzuki cross-coupling with an indazole boronic ester. The final step is a telescoped bis-methanesulfonylation and hydrolysis to yield the API. This report highlights experimental work on the final assembly sequence to establish robust processing conditions, minimize process mass intensity, control impurity formation, understand impurity purge, and enable large-scale manufacturing of lenacapavir sodium.</description><identifier>ISSN: 1083-6160</identifier><identifier>EISSN: 1520-586X</identifier><identifier>DOI: 10.1021/acs.oprd.4c00242</identifier><language>eng</language><publisher>American Chemical Society</publisher><ispartof>Organic process research & development, 2024-08, Vol.28 (8), p.3382-3395</ispartof><rights>2024 American Chemical Society</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-a163t-a89951d9d01be0c0a38f82ed0928686671770b4668812cef15e36bdcd720d5be3</cites><orcidid>0009-0002-8355-8597 ; 0009-0001-6258-3024</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://pubs.acs.org/doi/pdf/10.1021/acs.oprd.4c00242$$EPDF$$P50$$Gacs$$H</linktopdf><linktohtml>$$Uhttps://pubs.acs.org/doi/10.1021/acs.oprd.4c00242$$EHTML$$P50$$Gacs$$H</linktohtml><link.rule.ids>314,776,780,2752,27053,27901,27902,56713,56763</link.rule.ids></links><search><creatorcontrib>Wagner, Anna M.</creatorcontrib><creatorcontrib>Bonderoff, Sara A.</creatorcontrib><creatorcontrib>Chang, Stanley</creatorcontrib><creatorcontrib>Deignan, Jeffrey</creatorcontrib><creatorcontrib>Esanu, Michelle M.</creatorcontrib><creatorcontrib>Van Huynh, Huy</creatorcontrib><creatorcontrib>Niu, Tianmin</creatorcontrib><creatorcontrib>Ngo, Vinh</creatorcontrib><creatorcontrib>O’Keefe, B. Michael</creatorcontrib><creatorcontrib>Phoenix, Jenny</creatorcontrib><creatorcontrib>Rainey, Trevor J.</creatorcontrib><creatorcontrib>Roberts, Benjamin J.</creatorcontrib><creatorcontrib>Shen, Jinyu</creatorcontrib><creatorcontrib>Stewart, Craig</creatorcontrib><creatorcontrib>Vandehey, Amanda L.</creatorcontrib><creatorcontrib>Wolckenhauer, Scott A.</creatorcontrib><creatorcontrib>Wong, Chloe Y.</creatorcontrib><creatorcontrib>Yarmuch, Brian H.</creatorcontrib><title>Synthesis of Lenacapavir Sodium: Active Pharmaceutical Ingredient Process Development and Scale-up</title><title>Organic process research & development</title><addtitle>Org. Process Res. Dev</addtitle><description>Lenacapavir sodium (GS-6207-02) is a first-in-class HIV capsid inhibitor. Process development of the four-step final assembly of lenacapavir sodium from four synthetic intermediates is described here. A bis-bromopyridine core is sequentially subjected to an alkynylation, an amide coupling with a chiral pyrazole carboxylic acid, and a Suzuki cross-coupling with an indazole boronic ester. The final step is a telescoped bis-methanesulfonylation and hydrolysis to yield the API. This report highlights experimental work on the final assembly sequence to establish robust processing conditions, minimize process mass intensity, control impurity formation, understand impurity purge, and enable large-scale manufacturing of lenacapavir sodium.</description><issn>1083-6160</issn><issn>1520-586X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><recordid>eNp1kFFLwzAUhYMoOKfvPuYH2HmTrmnq25hOBwUHU_CtpMmty1ibkrSD_Xtbtlef7uXecw6Hj5BHBjMGnD0rHWau9WY21wB8zq_IhCUcokSKn-thBxlHggm4JXch7AEgEYxPSLk9Nd0Ogw3UVTTHRmnVqqP1dOuM7esXutCdPSLd7JSvlca-s1od6Lr59WgsNh3deKcxBPqKRzy4th5vqjF0O-gw6tt7clOpQ8CHy5yS79Xb1_Ijyj_f18tFHikm4i5SMssSZjIDrETQoGJZSY4GMi6FFCJlaQrlXAgpGddYsQRjURptUg4mKTGeEjjnau9C8FgVrbe18qeCQTEyKgZGxciouDAaLE9ny_jZu943Q8H_5X9sCGwV</recordid><startdate>20240816</startdate><enddate>20240816</enddate><creator>Wagner, Anna M.</creator><creator>Bonderoff, Sara A.</creator><creator>Chang, Stanley</creator><creator>Deignan, Jeffrey</creator><creator>Esanu, Michelle M.</creator><creator>Van Huynh, Huy</creator><creator>Niu, Tianmin</creator><creator>Ngo, Vinh</creator><creator>O’Keefe, B. Michael</creator><creator>Phoenix, Jenny</creator><creator>Rainey, Trevor J.</creator><creator>Roberts, Benjamin J.</creator><creator>Shen, Jinyu</creator><creator>Stewart, Craig</creator><creator>Vandehey, Amanda L.</creator><creator>Wolckenhauer, Scott A.</creator><creator>Wong, Chloe Y.</creator><creator>Yarmuch, Brian H.</creator><general>American Chemical Society</general><scope>AAYXX</scope><scope>CITATION</scope><orcidid>https://orcid.org/0009-0002-8355-8597</orcidid><orcidid>https://orcid.org/0009-0001-6258-3024</orcidid></search><sort><creationdate>20240816</creationdate><title>Synthesis of Lenacapavir Sodium: Active Pharmaceutical Ingredient Process Development and Scale-up</title><author>Wagner, Anna M. ; Bonderoff, Sara A. ; Chang, Stanley ; Deignan, Jeffrey ; Esanu, Michelle M. ; Van Huynh, Huy ; Niu, Tianmin ; Ngo, Vinh ; O’Keefe, B. Michael ; Phoenix, Jenny ; Rainey, Trevor J. ; Roberts, Benjamin J. ; Shen, Jinyu ; Stewart, Craig ; Vandehey, Amanda L. ; Wolckenhauer, Scott A. ; Wong, Chloe Y. ; Yarmuch, Brian H.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-a163t-a89951d9d01be0c0a38f82ed0928686671770b4668812cef15e36bdcd720d5be3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Wagner, Anna M.</creatorcontrib><creatorcontrib>Bonderoff, Sara A.</creatorcontrib><creatorcontrib>Chang, Stanley</creatorcontrib><creatorcontrib>Deignan, Jeffrey</creatorcontrib><creatorcontrib>Esanu, Michelle M.</creatorcontrib><creatorcontrib>Van Huynh, Huy</creatorcontrib><creatorcontrib>Niu, Tianmin</creatorcontrib><creatorcontrib>Ngo, Vinh</creatorcontrib><creatorcontrib>O’Keefe, B. Michael</creatorcontrib><creatorcontrib>Phoenix, Jenny</creatorcontrib><creatorcontrib>Rainey, Trevor J.</creatorcontrib><creatorcontrib>Roberts, Benjamin J.</creatorcontrib><creatorcontrib>Shen, Jinyu</creatorcontrib><creatorcontrib>Stewart, Craig</creatorcontrib><creatorcontrib>Vandehey, Amanda L.</creatorcontrib><creatorcontrib>Wolckenhauer, Scott A.</creatorcontrib><creatorcontrib>Wong, Chloe Y.</creatorcontrib><creatorcontrib>Yarmuch, Brian H.</creatorcontrib><collection>CrossRef</collection><jtitle>Organic process research & development</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Wagner, Anna M.</au><au>Bonderoff, Sara A.</au><au>Chang, Stanley</au><au>Deignan, Jeffrey</au><au>Esanu, Michelle M.</au><au>Van Huynh, Huy</au><au>Niu, Tianmin</au><au>Ngo, Vinh</au><au>O’Keefe, B. Michael</au><au>Phoenix, Jenny</au><au>Rainey, Trevor J.</au><au>Roberts, Benjamin J.</au><au>Shen, Jinyu</au><au>Stewart, Craig</au><au>Vandehey, Amanda L.</au><au>Wolckenhauer, Scott A.</au><au>Wong, Chloe Y.</au><au>Yarmuch, Brian H.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Synthesis of Lenacapavir Sodium: Active Pharmaceutical Ingredient Process Development and Scale-up</atitle><jtitle>Organic process research & development</jtitle><addtitle>Org. Process Res. Dev</addtitle><date>2024-08-16</date><risdate>2024</risdate><volume>28</volume><issue>8</issue><spage>3382</spage><epage>3395</epage><pages>3382-3395</pages><issn>1083-6160</issn><eissn>1520-586X</eissn><abstract>Lenacapavir sodium (GS-6207-02) is a first-in-class HIV capsid inhibitor. Process development of the four-step final assembly of lenacapavir sodium from four synthetic intermediates is described here. A bis-bromopyridine core is sequentially subjected to an alkynylation, an amide coupling with a chiral pyrazole carboxylic acid, and a Suzuki cross-coupling with an indazole boronic ester. The final step is a telescoped bis-methanesulfonylation and hydrolysis to yield the API. This report highlights experimental work on the final assembly sequence to establish robust processing conditions, minimize process mass intensity, control impurity formation, understand impurity purge, and enable large-scale manufacturing of lenacapavir sodium.</abstract><pub>American Chemical Society</pub><doi>10.1021/acs.oprd.4c00242</doi><tpages>14</tpages><orcidid>https://orcid.org/0009-0002-8355-8597</orcidid><orcidid>https://orcid.org/0009-0001-6258-3024</orcidid></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1083-6160 |
| ispartof | Organic process research & development, 2024-08, Vol.28 (8), p.3382-3395 |
| issn | 1083-6160 1520-586X |
| language | eng |
| recordid | cdi_crossref_primary_10_1021_acs_oprd_4c00242 |
| source | ACS Publications |
| title | Synthesis of Lenacapavir Sodium: Active Pharmaceutical Ingredient Process Development and Scale-up |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-09T16%3A03%3A19IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-acs_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Synthesis%20of%20Lenacapavir%20Sodium:%20Active%20Pharmaceutical%20Ingredient%20Process%20Development%20and%20Scale-up&rft.jtitle=Organic%20process%20research%20&%20development&rft.au=Wagner,%20Anna%20M.&rft.date=2024-08-16&rft.volume=28&rft.issue=8&rft.spage=3382&rft.epage=3395&rft.pages=3382-3395&rft.issn=1083-6160&rft.eissn=1520-586X&rft_id=info:doi/10.1021/acs.oprd.4c00242&rft_dat=%3Cacs_cross%3Ed184984191%3C/acs_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true |